Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | POLQ | O75417 | 5/20 | 0.34 |
| ▸ | MGLL | Q99685 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25254744 | 0.85 | SLC6A4 (0.41) | KCNH2CACNA1CSCN5AADAMTS5TACR1 | |
| SCHEMBL25294538 | 0.81 | POLB (0.41) | KCNH2CACNA1CSCN5AADAMTS5TACR1 | |
| SCHEMBL25290096 | 0.78 | MGLL (0.46) | KCNH2CACNA1CSCN5AADAMTS5MGLL | |
| SCHEMBL28986570 | 0.78 | KCNH2 (0.40) | KCNH2CACNA1CSCN5AADAMTS5TACR1 | |
| SCHEMBL25297074 | 0.78 | MGLL (0.46) | KCNH2CACNA1CSCN5AADAMTS5MGLL | |
| SCHEMBL25254799 | 0.78 | MGLL (0.46) | KCNH2CACNA1CSCN5AADAMTS5MGLL | |
| SCHEMBL25253335 | 0.74 | TEAD1 (0.44) | KCNH2CACNA1CSCN5AADAMTS5 | |
| SCHEMBL25262919 | 0.72 | ENPP2 (0.39) | KCNH2CACNA1CSCN5AADAMTS5MGLL | |
| SCHEMBL25253607 | 0.71 | CACNA1B (0.39) | ADAMTS5MGLL | |
| SCHEMBL29497045 | 0.69 | USP30 (0.33) | TACR1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | KCNH2 792/4885CACNA1C 1547/4885SCN5A 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.